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Abstract
Deep vein thrombosis (DVT) is a common disease, especially among elderly patients, which is associated with high costs of 
treatment and high rates of recurrence. The risk factors for venous thrombosis are primarily related to hypercoagulability, 
which can be genetic or acquired, or because of immobilization and venous stasis. Among relevant genetic markers are a 
number of common polymorphisms and mutations in the genes coding for Factor V leiden and methylenetetrahydrofolate 
reductase. Differential associations of these polymorphisms have been reported in different populations with DVT due to 
ethnic variations. However, no study has been reported with respect to these polymorphisms in DVT in Iran. Thus, the aim 
of the present study is to determine the prevalence of FVL, MTHFR C677T and MTHFR A1298C gene polymorphisms in 
patients with DVT in central Iran. In the present cross-sectional study, a total of 100 patients with first and recurrent epi-
sodes of DVT and age less than 70 years were recruited during 2016–2017. Blood sample was collected from the recruited 
patients and FVL mutation was screened using ARMS-PCR method, MTHFR C677T and MTHFR A1298C mutations were 
screened using PCR-RFLP method. The results revealed that MTHFR A1298C gene polymorphism in both homozygote 
and heterozygote form was found to be most frequent i.e. 77% among cases, followed by MTHFR C677T (67%) and FVL 
(17%). The study highlights the importance of screening of these genetic markers among patients with DVT in this region.
Keywords Deep vein thrombosis · Factor V leiden (FVL) · Methylene tetrahydrofolate reductase (MTHFR) C677T and 
A1298C polymorphisms
Introduction
Venous thromboembolism (VTE) includes deep vein throm-
bosis (DVT) and pulmonary embolism (PE) [1]. DVT is 
one of the most prevalent medical problems today, with 
an annual incidence of 80 cases per 100,000 globally [2]. 
Although there is no national registry system for keeping 
VTE records in Iran, some previous studies estimated that 
the mean annual prevalence rate of DVT among Iranian 
population is approximately between 832 and 2528 cases 
per 100,000 patients [3].
Deep vein thrombosis (DVT) is a common disease, espe-
cially among elderly patients, which is associated with high 
costs of treatment and high rates of recurrence [2, 4]. The 
risk factors for venous thrombosis are primarily related to 
hypercoagulability, which can be genetic or acquired, or 
because of immobilization and venous stasis. The major 
acquired risk factors are hospitalization due to acute illness 
or major orthopedic, abdominal or neurologic surgeries, pro-
longed bedrest, malignant neoplasm, acute extremity paresis, 
trauma or fracture, superficial veins thrombosis, pregnancy, 
oral contraceptive use, increasing age, obesity, smoking, 
heart failure and hormone replacement therapy [4].
Genetic predisposition to DVT may be result into loss of 
function of endogenous coagulants such as ant thrombin III, 
protein S/protein C or increase in procoagulant proteins such 
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as FVL, factor VIII. Several genetic mutations have been 
associated with these proteins of which mutations in FVL 
and MTHFR genes have been widely studied.
Previous studies show that Factor V Leiden and MTHFR 
C677T are the most common polymorphic variants which 
cause thrombophilia. While FVL is known as a significant 
risk factor for VTE, the role of MTHFR C677T and MTHFR 
A1298C polymorphisms is still in controversy. For instance, 
Gohil et al. [5] indicated that heterozygous FVL significantly 
increase the risk of VTE by 9.45-fold. This is while the 
results of their study showed that MTHFR C677T increased 
the risk of VTE in 57% of Chinese population whereas in 
Caucasians no significant association was found [5]. Also 
researchers have shown that homozygous variant of MTHFR 
C677T is observed in less than 1% of African American 
cases while 11% among Asian populations [6]. On the other 
hand, Sabbagh et al. found out about the 50.2% prevalence 
of MTHFR A1298C among DVT cases in Lebanon [7] while 
Saraswathy et al. found MTHFR A1298C in less than 1% of 
some Indian populations [8]. Finally, Rahimi et al. screened 
FVL and MTHFR C677T prevalence in western Iran and 
found they are prevalent among 11.4 and 38.7% in the DVT 
patients respectively [9].
In order to investigate the prevalence of FVL, MTHFR 
C677T and MTHFR A1298C polymorphisms in the patients 
with DVT in Iran, the present study was conducted in 
Kashan’s Shahid Beheshti Hospital which is located in cen-
tral Iran.
Materials and methods
Patients
In this cross-sectional study we enrolled 100 patients with 
first and recurrent episodes of DVT and age less than 
70 years (male/female [M/F] 57/43, median age, 41.53 
years, range 19–68). These patients were recruited regarding 
their general characteristics such as gender, age and ethnic-
ity. All diagnosis of DVT had been confirmed by Doppler 
ultrasonography (DU) during 2016–2017. In all patients, 
the DVT was idiopathic because those with other circum-
stantial risk factors (such as hemophilia, thrombocytopenia, 
disseminated intravascular coagulation, oral contraceptives, 
surgery, trauma, prolonged immobilization, active cancer 
and smoking history) were excluded from the study. All 
subjects gave their informed consent to the study and the 
study was approved by the Ethics Committee of Kashan’ 
Shahid Behesti University.
Methods
About 10 cc of venous blood samples were drawn into 
syringe containing EDTA. These syringes were kept at 
− 20 °C. DNA was extracted by phenol chloroform method 
and evaluated using a spectrophotometer in two wave-
lengths of 260 and 280 nm. ARMS-PCR method was used 
to determine the mutation of FVL using 2 toward-specific 
primers, 1 normal primer, 1 mutant primer and a third 
primer as a common reverse primer [10]. Also restric-
tion fragment length polymorphism (RFLP-PCR) method 
was used to determine MTHFR mutations (Table 1). The 
amplified PCR products of C677T and A1298C were sepa-
rately digested with HinfI and MboII restriction enzymes 
respectively (New England Biolabs, USA). After diges-
tion, products were subjected to electrophoresis on 2% 
agarose. The digestion fragment sizes for C677T geno-
types were: a single 198 bp band for CC, 198, 175 and 
23 bp for CT, and 175 and 23 bp for TT. Digestion of PCR 
product with MboII for 1298AA genotype produces frag-
ments of 72, 37, and 28 bp, whereas mutant CC genotype 
generates fragments of 100 and 28 bp, and heterozygous 
AC genotype produces fragments of 100, 72, and 28 bp. 
Finally, the products of enzymatic digestion were loaded 
on a polyacrylamide gel 8% at a voltage of 150 and for 5 h 
and mutations were detected using a specific pattern that 
generated each mutation.
Statistical analysis
All statistical analysis of the study was done by SPSS 16 
software. In case of need for a statistical test, t-test or 
Fischer’s test were used based on the type of independent 
and dependent variables as well as the type of variables 
distribution.
Table 1  Primers sequences
Primer name Sequence
FVL
 FVL-F ACA TCT TAG AGT TTG ATG A
 FVL (normal)-R GGA CAA AAT ACC TGT ATT CCGC 
 FVL (mutant)-R GGA CAA AAT ACC TGT ATT CCCT 
MTHFR C677T
 C677T-F TGA AGG AGA AGG TGT CTG CGGGA 
 C677T-R AGG ACG GTG CGG TGA GAG TG
MTHFR A1298C
 A1298C-F GCA AGT CCC CCA AGG AGG 
 A1298C-R GGT CCC CAC TTC CAG CAT C
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Results
The present study is trying to investigate the prevalence of 
FVL, MTHFR A1298C and C677T polymorphisms among 
DVT patients in Central Iran. Table 2 shows the results.
Analyzing the results of homozygous, heterozygous and 
wild type mutations show that the prevalence of FVL muta-
tion is 17% (10% heterozygous and 7% homozygous) while 
MTHFR C677T is observed in 67% (49% heterozygous and 
18% homozygous) of the patients and MTHFR A1298C is 
prevalent among 77% (63% heterozygous and 14% homozy-
gous) of patients with DVT in this region.
Also, No gender based differences were observed in DVT 
patients with respect to FVL, MTHFR C677T and MTHFR 
A1298C gene polymorphisms (p > 0.05).
Discussion
We determined the frequency of FVL and MTHFR A1298C 
and C677T polymorphisms among patients of deep vein 
thrombosis to know the odds of these mutations in DVT 
patients. The main aim of this study was to document the 
prevalence of the aforementioned mutations in Central Iran. 
While prevalence of FVL varies from 0 to 15% according 
to ethnicity and geographic distribution worldwide [11], the 
results of studies in Iranian Plateau reveal higher rates of 
FVL in DVT patients (from 8 to 28%) [9, 11, 12].
Likewise, previous studies showed mixed results on 
the prevalence of MTHFR C677T polymorphism in DVT 
patients and the correlation between C677T and DVT is 
still a controversial issue. Some researchers found lower fre-
quencies of this polymorphism among their cases (such as 
4.2% in Simone’s study [13]) but Dolek found that C677T is 
prevalent among 49.6% of Turkish populations [12]. Unlike 
FVL and C677T, the role of A1298C polymorphism in DVT 
patients has not gained enough attention in the literature. 
However, those researchers who studied this polymorphism 
have showed relatively high frequencies. For instance, 
Ramacciotti et al. found out that 53.1% DVT patients have 
MTHFR A1298C [14].
The results of the present study demonstrated that the 
frequency of MTHFR C677T (67%) and A1298C (77%) 
polymorphisms is dramatically high among DVT patients 
in Central Iranian populations. In addition, the study showed 
that the prevalence of FVL among our patients (17%) is 
higher than some populations like Pakistanis but lower than 
some others such as some Turkish populations (see Table 3).
The difference between frequency of FVL, MTHFR 
C667T and A1298 in this population and other populations 
might be because of differences in sample sizes, ethnicity 
and geographical conditions. One of the geographical con-
ditions of the studied population is that the city has been 
historically a relatively small town in the desert and reluctant 
to accept other ethnicities. Thus consanguineous marriages 
have been prevalent so that among 100 cases of the present 
study, 18 consanguinity cases were observed.
Finally, cases were tested for the assumption of 
Hardy–Weinberg Equilibrium (HWE) with respect to FVL, 
MTHFR C677T and MTHFR A1298C polymorphisms. The 
results showed that cases were in HWE only for MTHFR 
C677T whereas FVL and MTHFR A1298C polymorphisms 
among cases were not in this equilibrium. Although some 
researchers believe that such deviation from HWE might 
be resulted from genotyping error but some others argue 
that it is not surprising because the assumptions underly-
ing this equilibrium—i.e. the absence of evolutionary influ-
ences such as migration or random mating—are rarely seen 
in human population [17]. As mentioned before, Kashan has 
almost an isolated population which can be a probable rea-
son for FVL and MTHFR A1298C polymorphisms not being 
in HWE. Since homozygotes are overrepresented compared 
to expected HWE values, inbreeding could be a possible 
Table 2  The prevalence of FVL, 
MTHFR C677T and MTHFR 
A1298C polymorphisms in the 
patients with DVT
FVL MTHFR A1298C MTHFR C677T
GG GA AA AA AC CC CC CT TT
Male (n = 57) 50 6 1 25 32 0 22 26 9
Female (n = 43) 38 4 1 12 31 0 18 23 2
Table 3  Frequency of FVL, MTHFR C677T and MTHFR A1298C polymorphisms among different population (%)
Populations Western Iranians Pakistanis Turkish Italians East Europeans South Indians Central Iran
References Rahimi [9] Saeed et al. [11] Dolek [12] Simone [13] Tug [15] Naushad [16] This study
FVL 11.4 13% 28.3 19.3 11.7 8.6 17
C677T 38.7 – 49.6 4.2 30.4 18.4 67
A1298C – – 62.9 – 39.1 61.3 77
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reason for this finding. Also other possibilities such as under 
selection locus, null alleles and Wahlunds’ Effect can be 
considered for such finding but because of the demographic 
and geographic information, inbreeding can be recognized 
as the main reason.
Conclusion
The study revealed that factor V leiden and MTHFR muta-
tions (both C677T and A1298C in each homozygous or 
heterozygote forms) in DVT patients in central Iran is very 
prevalent. Evaluation of these mutations in patients with 
DVT can result in cost reduction for public health, determi-
nation of treatment duration for the patient and considering 
prophylactic procedures for patients’ family members who 
have such mutations.
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